Alere Unloads Its Triage Assets To Quidel

The deal, subject to the completion of Abbott's planned acquisition of Alere, includes the Triage MeterPro cardiovascular and toxicology businesses, as well as the Triage BNP business. These additions will diversify Quidel's portfolio of rapid diagnostic products for critical care settings and give it a stronger presence in the point-of-care market.

Quidel Corp. will pay up to $440m to acquire Alere Inc.'s Triage business as Alere prepares to become part of Abbott Laboratories Inc., the companies announced July 18.

Quidel will pay $400m up-front and up to $40m in contingent considerations to acquire the real estate for the Triage...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from In Vitro Diagnostics

More from Diagnostics